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AntibacterialsIn vitro activity of tedizolid and comparators against 11,231 Gram-positive clinical isolates from the United States
(84 centers) and Europe (115 centers) were summarized as part of the Surveillance of Tedizolid Activity and Resis-
tance program between 2009 and 2013. Susceptibility testing was performed according to Clinical Laboratory and
Standards Institute (CLSI) guidelines. Minimum inhibitory concentration (MIC) interpretations were based on CLSI
and European Committee on Antimicrobial Susceptibility Testing criteria. Tedizolid inhibited 99.7% of all isolates at
MIC ≤0.5mg/L; activitywas similar regardless ofmethicillin or vancomycin resistance phenotypes of Staphylococcus
aureus and enterococci, respectively. Tedizolid MIC N1 mg/L was reported for 3 S. aureus, 4 coagulase-negative
staphylococci, and 2 enterococcal isolates; all streptococci were inhibited at MIC ≤0.5 mg/L. Tedizolid was ≥4-fold
more potent than linezolid against all groups, including resistant phenotypes. Tedizolid had potent/stable activity
against a large, contemporary collection of Gram-positive clinical isolates, with low rates of resistance.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tedizolid phosphate, the prodrug of the oxazolidinone antibacterial
tedizolid, is approved in the United States and a number of countries
in the European Union for the treatment of acute bacterial skin and
skin structure infections (ABSSSI) (Merck Sharp & Dohme Corp., 2015;
Merck Sharp & Dohme Ltd., 2016). Two Phase 3 randomized, double-
blind clinical trials in patients with ABSSSI demonstrated that the efﬁca-
cy of tedizolid 200 mg once daily for 6 days was noninferior to that of
linezolid 600mg twice daily for 10 days and that tedizolid was well tol-
erated (Moran et al., 2014; Prokocimer et al., 2013).
Tedizolid exerts its antibacterial activity by binding to the 50S sub-
unit of the bacterial ribosome, resulting in inhibition of protein synthe-
sis (Shaw et al., 2008). Multiple elements in the structure of tedizolid
allow additional interactions and tighter binding at the target site, lead-
ing to a greater potency of tedizolid compared with linezolid (Lockestructure infections; BHS, β-
istance gene; CLSI, Clinical Labo-
streptococci; EUCAST, European
ternational HealthManagement
Methicillin resistant Staphylococ-
reus; optrA, Oxazolidinone resis-
esistance; VGS, Viridans group
sceptible.
1-267-305-6529.
ci).
. This is an open access article underet al., 2010a; Shaw et al., 2008). Based on MIC values that inhibited
the growth of 90% of isolates (MIC90), tedizolid is generally at least
4-fold more potent in vitro than linezolid against susceptible strains
of staphylococci, streptococci, and enterococci, including methicillin-
and vancomycin-resistant strains (Brown and Traczewski, 2010;
Prokocimer et al., 2012; Schaadt et al., 2009; Shaw et al., 2008; Thomson
and Goering, 2013).
Tedizolid also shows potent activity against certain linezolid-
resistant strains (Livermore et al., 2009; Locke et al., 2010b; Shaw
et al., 2008). Resistance to linezolid is not common (Mendes et al.,
2014); however, several classes of resistance have been described for
oxazolidinones. Chromosomal mutations that affect 23S rRNA or ribo-
somal proteins L3 and L4 account for the majority of linezolid-
resistant strains (Long and Vester, 2012; Prystowsky et al., 2001;
Tsiodras et al., 2001). Resistance to linezolid can also be conferred by
the plasmid-borne chloramphenicol-ﬂorfenicol resistance gene (cfr),
which leads to methylation of 23S RNA and obstructs the binding of
multiple antibacterial agents (Kaminska et al., 2010; Locke et al.,
2010b; Long et al., 2006; Smith and Mankin, 2008).
Because of its more compact A-ring hydroxymethyl chain, these
conformational changes do not affect tedizolid binding; hence, it retains
activity against linezolid-resistant cfr-bearing strains (Locke et al.,
2010a; Shaw et al., 2008). Recently, a novel oxazolidinone resistance
gene (optrA) was identiﬁed in Enterococcus faecium and Enterococcus
faecalis isolates from China that confers transferable resistance or
elevated MICs (when no clinical breakpoints were available) tothe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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col and ﬂorfenicol) (Wang et al., 2015). Whether this resistance mech-
anism is conﬁrmed, remains to be elucidated. The Surveillance of
Tedizolid Activity and Resistance (STAR) study is an ongoing program
that compares the in vitro activity of tedizolid and other antibacterial
agents against a variety of clinically relevant Gram-positive pathogens
and monitors the emergence of resistance. Herein, we report 5 years
of STAR program surveillance data (2009–2013) on more than 11,000
isolates collected in the United States and Europe.
2. Methods
2.1. Collection of bacterial isolates
Antibacterial susceptibility testingwas conducted by EuroﬁnsGlobal
Central Laboratory (Chantilly, VA, USA) and International Health
Management Associates (IHMA), Inc. (Schaumburg, IL, USA). A total
of 11,231 nonduplicate, nonconsecutive isolates of staphylococci, strep-
tococci, and enterococci were collected from multiple locations in
the United States and Europe, including samples from bloodstream in-
fection, pneumonia in hospitalized patients, skin/soft tissue infection,
urinary tract infection, intra-abdominal infection, and respiratory tract
infection. The distribution of pathogen species is shown in Table 1.
Of the 11,231 isolates, 8912 were collected from 84 hospitals across 9
US census regions and 2319 were collected from 115 sites in 21
European countries.
2.2. Susceptibility testing
Upon receipt of the isolates, species identiﬁcation was conﬁrmed by
Matrix Assisted Laser Desorption Ionization Biotyper (Bruker, Fremont,
CA, USA) using the MBT Compass library RUO 5989. Susceptibility test-
ing was performed by broth microdilution in accordance with the
guidelines of the Clinical Laboratory and Standards Institute (CLSI)
M07-A9 (Clinical and Laboratory Standards Institute, 2012a) and CLSI
M100-S22 (Clinical and Laboratory Standards Institute, 2012b) and in
accordance with the standard operating procedures at the testing labo-
ratories. Quality control and interpretation of results were performed
in accordance with CLSI M100-S22 methods. The MICs of isolates
with tedizolid MIC values N0.5 mg/L or linezolid MIC values N4 mg/LTable 1
Distribution of organisms collected as part of the STAR program in the United States and
Europe, 2009–2013.
United States Europe Total
Staphylococcus aureus 6237 1576 7813
MRSA 2858 376 3234
MSSA 3379 1200 4579
CoNSa 504 119 623
BHS 1148 321 1469
Streptococcus agalactiae 568 147 715
Streptococcus pyogenes 530 154 684
Other BHSb 50 20 70
VGSc 30 21 51
Enterococci 993 282 1275
E. faecalis 702 166 868
E. faecium 267 105 372
Other enterococcid 24 11 35
Total 8912 2319 11,231
BHS = β-hemolytic streptococci; CoNS = coagulase-negative staphylococci; MRSA =
methicillin resistant Staphylococcus aureus; MSSA = methicillin-susceptible Staphylococ-
cus aureus; VGS = viridans group streptococci.
a CoNS include S. capitis, S. caprae, S. cohnii, S. epidermidis, S. haemolyticus, S. hominis,
S. intermedius, S. pasteuri, S. pettenkoferi, S. saprophyticus, S. schleiferi, S. sciuri, S. simulans,
S. warneri, and S. xylosus.
b Other BHS include group C, group F, and group G streptococci.
c VGS include S. anginosus, S. constellatus, and nonspeciated Streptococcus.
d Other enterococci include E. casseliﬂavus, E. durans, E. gallinarum, E.mundtii, E. rafﬁnosus,
and nonspeciated enterococci.were reconﬁrmed by broth microdilution testing in accordance with
CLSI guidelines.
Isolates were tested with MIC panels (ThermoFisher Scientiﬁc,
Cleveland, OH, USA, and IHMA) of antibiotics appropriate for their
class (as listed in Table 2). MIC interpretations for tedizolid were
based on CLSI and European Committee on Antimicrobial Susceptibility
Testing (EUCAST) breakpoint criteria. The following CLSI breakpoints
were applied: ≤0.5 mg/L (susceptible), 1 mg/L (intermediate) and ≥2
mg/L (resistant) for Staphylococcus aureus (including methicillin-
resistant Staphylococcus aureus [MRSA] isolates); ≤0.5 mg/L (suscepti-
ble) for Enterococcus faecalis, Streptococcus pyogenes, and Streptococcus
agalactiae; and ≤0.25 mg/L (susceptible) for Streptococcus anginosus
group isolates (ie, S. anginosus, S. intermedius, and S. constellatus)
(Merck Sharp & Dohme Corp., 2015). The following EUCAST breakpoints
were applied (Merck Sharp & Dohme Ltd., 2016): ≤0.5 mg/L (suscepti-
ble) and N0.5mg/L (resistant) for Staphylococcus spp. and BHS (β-hemolytic
streptococci; groups A, B, C, and G); and ≤0.25 mg/L (susceptible) and
N0.25 mg/L (resistant) for S. anginosus group isolates. Susceptibility re-
sults for comparator agents were interpreted according to CLSI and
EUCAST criteria (Clinical and Laboratory Standards Institute, 2015;
European Committee on Antimicrobial Susceptibility Testing, 2015).
3. Results
3.1. Overall activity of tedizolid from 2009 to 2013
Over the 5 years tested, tedizolid maintained excellent activity
against key target pathogens, including strains with resistant pheno-
types. Table 2 shows the activity proﬁle of tedizolid and comparators
against target pathogens. Table 3 shows the cumulative percentage of
isolates inhibited at each tedizolid MIC value; for comparison, the cu-
mulative percentages of isolates inhibited at each linezolid MIC value
are shown in Table 4. Tedizolid MIC values ranged from ≤0.008 to 4
mg/L, and 99.7% of 11,231 isolates were inhibited at MIC ≤0.5 mg/L.
Based on MIC90, tedizolid was 4- to 8-fold more potent than linezolid.
Tedizolid was active against Gram-positive strains that were resistant
to commonly used antibacterial agents.
3.2. Activity of tedizolid against S. aureus
Tedizolid had highly potent activity against S. aureus isolates over
the 5 years of surveillance, with MIC50 and MIC90 values 0.25 and 0.5
mg/L, respectively, and modal MIC 0.25 mg/L. Of 7813 isolates, 0.2%
were nonsusceptible to tedizolid MIC N0.5 mg/L. For linezolid, the MIC
ranged from 0.12 to 8 mg/L, and MIC50 and MIC90 were both 2 mg/L.
Tedizolid was active against S. aureus that was resistant to clindamycin,
erythromycin, levoﬂoxacin, and trimethoprim/sulfamethoxazole.
Tedizolid maintained activity against S. aureus regardless of methi-
cillin susceptibility, with MIC50 and MIC90 values 0.25 mg/L and
0.5 mg/L, respectively, against both MRSA and methicillin-resistant
Staphylococcus aureus (MSSA). In comparison, linezolid MIC50 and
MIC90 were 2mg/L against eitherMRSA orMSSA. Limited anti-MRSA ac-
tivity was also reported for clindamycin, erythromycin, and levoﬂoxacin.
The proportion of MRSA was higher among S. aureus isolates from the
United States (45.8%) than among those from Europe (23.9%).
Of 7813 S. aureus isolates, 19 were nonsusceptible to tedizolid
(based on both CLSI and EUCAST breakpoints), with MIC N0.5 mg/L. Of
these tedizolid nonsusceptible isolates, 14 (all with tedizolid MIC
1mg/L) remained susceptible to linezolid according to CLSI breakpoints,
with MICs of 1 mg/L (4 isolates), 2 mg/L (4 isolates), or 4 mg/L (6 iso-
lates). Based on CLSI breakpoints, 16/19 nonsusceptible isolates were
considered to have intermediate susceptibility to tedizolid since their
MIC was 1 mg/L (CLSI intermediate category deﬁned as MIC = 1
mg/L); however, these isolates were considered resistant based on
EUCAST-approved breakpoints (resistant category deﬁned as MIC N0.5
mg/L). The remaining three nonsusceptible isolates were tedizolid
Table 2
Activity proﬁle of tedizolid and comparators against isolates collected in the United States and Europe, 2009–2013.
CLSI EUCAST
Organism Drug Range (mg/L) MIC50 (mg/L) MIC90 (mg/L) %S %I %R %S %I %R
Staphylococcus aureus (n = 7813) Tedizolid ≤0.015 to 2 0.25 0.5 99.8 0.2 0.0 99.8 — 0.2
Linezolid 0.12 to 8 2 2 99.9 0.0 0.1 99.9 0.0 0.1
Clindamycin ≤0.03 to N16 0.12 N4 83.5 0.2 16.3 83.0 0.5 16.5
Daptomycin ≤0.06 to 4 0.5 0.5 99.8 0.0 0.2 99.8 0.0 0.2
Erythromycin ≤0.12 to N8 N8 N8 39.6 4.0 56.4 42.8 0.2 57.0
Levoﬂoxacin ≤0.03 to N32 0.25 16 62.5 1.7 35.8 62.5 1.7 35.8
Tigecycline ≤0.008 to 1 0.06 0.25 99.9 0.0 0.1 99.9 0.0 0.1
TMS ≤0.5 to N4 ≤0.5 ≤0.5 98.6 0.0 1.4 98.6 0.3 1.1
Vancomycin 0.12 to 2 0.5 1 100.0 0.0 0.0 100.0 0.0 0.0
MRSA (n = 3234) Tedizolid ≤0.015 to 2 0.25 0.5 99.6 0.3 0.1 99.6 0.0 0.4
Linezolid ≤0.25 to 8 2 2 99.8 0 0.2 99.7 0.0 0.3
Clindamycin ≤0.03 to N16 0.12 N16 68.3 0.2 31.5 67.8 0.5 31.7
Daptomycin ≤0.06 to 4 0.5 0.5 99.7 0.0 0.3 99.7 0.0 0.3
Erythromycin ≤0.12 to N8 N8 N8 9.8 1.6 88.6 10.7 0.1 89.2
Levoﬂoxacin 0.06 to N32 4 32 28.9 2.1 69.0 28.9 2.1 69.0
Tigecycline ≤0.015 to 1 0.06 0.25 99.8 0.0 0.2 99.8 0.0 0.2
TMS ≤0.5 to N4 ≤0.5 ≤0.5 97.6 0.0 2.4 97.6 0.4 2.0
Vancomycin ≤0.25 to 2 0.5 1 100.0 0.0 0.0 100.0 0.0 0.0
MSSA (n = 4579) Tedizolid ≤0.015 to 1 0.25 0.5 99.9 0.1 0.0 99.9 0.0 0.1
Linezolid 0.12 to N4 2 2 100.0 0.0 0.0 100.0 0.0 0.0
Clindamycin ≤0.03 to N16 0.12 0.25 94.3 0.2 5.5 93.7 0.6 5.7
Daptomycin ≤0.06 to 4 ≤0.5 0.5 99.8 0.0 0.2 99.9 0.0 0.1
Erythromycin ≤0.12 to N8 0.5 N8 60.7 5.7 33.6 65.4 0.4 34.2
Levoﬂoxacin ≤0.03 to N32 0.12 4 86.2 1.3 12.5 86.2 1.3 12.5
Tigecycline ≤0.008 to 0.5 0.06 0.25 100.0 0.0 0.0 100.0 0.0 0.0
TMS ≤0.5 to N4 ≤0.5 ≤0.5 99.3 0.0 0.7 99.3 0.3 0.4
Vancomycin 0.12 to 2 0.5 1 100.0 0.0 0.0 100.0 0.0 0.0
CoNS (n = 623) Tedizolid ≤0.008 to 4 0.12 0.25 — — — 99.0 0.0 1.0
Linezolid ≤0.008 to N4 1 2 99.4 0.0 0.6 99.4 0.0 0.6
Clindamycin ≤0.03 to N16 0.12 N4 67.3 2.7 30.0 65.0 2.3 32.7
Daptomycin ≤0.06 to 2 0.5 0.5 99.8 0.0 0.2 99.8 0.0 0.2
Erythromycin ≤0.12 to N8 N8 N8 34.4 1.1 64.5 34.5 0.3 65.2
Levoﬂoxacin ≤0.03 to N32 1 N32 50.6 3.2 46.2 50.6 3.2 46.2
Tigecycline ≤0.008 to 0.5 0.12 0.25 100.0 0.0 0.0 100.0 0.0 0.0
Vancomycin ≤0.004 to 2 1 2 100.0 0.0 0.0 100.0 0.0 0.0
BHS (n = 70) Tedizolid ≤0.008 to 0.25 0.12 0.25 — — — 100.0 0.0 0.0
Linezolid ≤0.008 to 2 1 1 100.0 0.0 0.0 100.0 0.0 0.0
Ceftriaxone ≤0.015 to 0.25 0.03 0.25 100.0 0.0 0.0 — — —
Clindamycin ≤0.015 to N2 0.06 0.12 91.4 0.0 8.6 91.4 0.0 8.6
Daptomycin ≤0.03 to 0.5 0.06 0.25 100.0 0.0 0.0 100.0 0.0 0.0
Erythromycin ≤0.015 to N4 0.06 N4 71.4 0.0 28.6 71.4 0.0 28.6
Levoﬂoxacin ≤0.004 to N4 0.5 0.5 97.1 0.0 2.9 97.1 0.0 2.9
Penicillin ≤0.03 to 0.12 ≤0.06 ≤0.06 100.0 0.0 0.0 100.0 0.0 0.0
Vancomycin ≤0.0005 to 1 0.25 0.5 100.0 0.0 0.0 100.0 0.0 0.0
Streptococcus agalactiae (n = 715) Tedizolid ≤0.015 to 0.5 0.25 0.25 100.0 0.0 0.0 100.0 0.0 0.0
Linezolid ≤0.12 to 2 1 1 100.0 0.0 0.0 100.0 0.0 0.0
Ceftriaxone ≤0.015 to 0.25 0.06 0.06 100.0 0.0 0.0 0.0 0.0 0.0
Clindamycin ≤0.015 to N2 0.06 N2 74.2 1.0 24.8 75.2 0.0 24.8
Daptomycin ≤0.03 to N1 0.25 0.25 99.9 0.0 0.1 99.9 0.0 0.1
Erythromycin ≤0.015 to N32 0.06 N4 51.3 1.4 47.3 51.3 1.4 47.3
Levoﬂoxacin 0.12 to N8 0.5 1 99.2 0.1 0.7 98.1 1.1 0.8
Penicillin ≤0.03 to 0.12 ≤0.06 0.06 100.0 0.0 0.0 100.0 0.0 0.0
Vancomycin ≤0.06 to 1 0.25 0.5 100.0 0.0 0.0 100.0 0.0 0.0
Streptococcus pyogenes (n = 684) Tedizolida ≤0.015 to 0.25 0.12 0.25 100.0 0.0 0.0 100.0 0.0 0.0
Linezolid ≤0.12 to 1 1 1 100.0 0.0 0.0 100.0 0.0 0.0
Ceftriaxone ≤0.015 to 0.25 ≤0.015 0.03 100.0 0.0 0.0 0.0 0.0 0.0
Clindamycin ≤0.015 to N2 0.06 0.06 96.9 0.2 2.9 97.1 0.0 2.9
Daptomycin ≤0.03 to N1 0.06 0.12 99.8 0.0 0.2 99.8 0.0 0.2
Erythromycin ≤0.015 to N32 0.06 4 86.5 0.6 12.9 86.5 0.6 12.9
Levoﬂoxacin ≤0.004 to 4 0.5 1 99.8 0.2 0.0 93.9 6.0 0.1
Penicillin ≤0.03 to 0.12 ≤0.06 ≤0.06 100.0 0.0 0.0 100.0 0.0 0.0
Vancomycin ≤0.06 to 0.5 0.25 0.25 100.0 0.0 0.0 100.0 0.0 0.0
Viridans group streptococci (n = 51) Tedizolid ≤0.015 to 0.25 0.12 0.25 — — — — — —
Linezolid ≤0.06 to 1 0.5 1 100.0 0.0 0.0 — — —
Ceftriaxone ≤0.015 to 1 0.25 0.25 100.0 0.0 0.0 98.0 0.0 2.0
Clindamycin ≤0.015 to N0.5 0.03 0.25 92.1 0.0 7.9 88.2 0.0 11.8
Daptomycin 0.06 to N0.5 0.25 0.5 100.0 0.0 0.0 — — —
Erythromycin ≤0.015 to N32 ≤0.015 2 80.4 5.9 13.7 — — —
Levoﬂoxacin ≤0.25 to 8 0.5 1 96.0 2.0 2.0 — — —
Penicillin ≤0.03 to 0.25 ≤0.03 0.06 98.0 2.0 0.0 100.0 0.0 0.0
Vancomycin ≤0.06 to 1 0.5 1 100.0 0.0 0.0 100.0 0.0 0.0
Other enterococci (n = 35) Tedizolid 0.12 to 0.5 0.25 0.5 — — — — — —
Linezolid 0.5 to 4 1 2 97.1 2.9 0.0 100.0 0.0 0.0
(continued on next page)
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Table 2 (continued)
CLSI EUCAST
Organism Drug Range (mg/L) MIC50 (mg/L) MIC90 (mg/L) %S %I %R %S %I %R
Ampicillin 0.25 to N16 0.5 N16 65.7 0.0 34.3 65.7 0.0 34.3
Daptomycin 0.12 to 4 1 4 100.0 0.0 0.0 — — —
Levoﬂoxacin 0.25 to N32 1 N32 68.6 0.0 31.4 68.6 0.0 31.4
Tigecycline ≤0.008 to 0.25 0.06 0.12 100.0 0.0 0.0 100.0 0.0 0.0
Vancomycin ≤0.25 to N32 1 N32 77.1 2.9 20.0 77.1 0.0 22.9
Other enterococci VS (n = 27) Tedizolid 0.12 to 0.5 0.25 0.5 — — — — — —
Linezolid 0.5 to 4 2 2 96.3 3.7 0.0 100.0 0.0 0.0
Ampicillin 0.25 to N16 0.5 N16 81.5 0.0 18.5 81.5 0.0 18.5
Daptomycin 0.12 to 4 0.5 2 100.0 0.0 0.0 — — —
Levoﬂoxacin 0.25 to N32 1 N4 85.2 0.0 14.8 85.2 0.0 14.8
Tigecycline ≤0.008 to 0.25 ≤0.015 0.12 100.0 0.0 0.0 100.0 0.0 0.0
Vancomycin ≤0.25 to 4 0.5 4 100.0 0.0 0.0 100.0 0.0 0.0
Enterococcus faecalis (n = 868) Tedizolid ≤0.015 to 1 0.25 0.5 99.42 — — — — —
Linezolid ≤0.25 to 2 1 2 100.0 0.0 0.0 100.0 0.0 0.0
Ampicillin ≤0.12 to N16 1 1 99.3 0.0 0.7 99.2 0.1 0.7
Daptomycin ≤0.06 to 4 1 2 100.0 0.0 0.0 — — —
Levoﬂoxacin ≤0.03 to N32 1 N32 67.5 0.4 32.1 67.9 0.0 32.1
Tigecycline ≤0.008 to 0.25 0.06 0.12 100.0 0.0 0.0 100.0 0.0 0.0
Vancomycin 0.12 to N32 1 2 95.5 0.2 4.3 95.5 0.0 4.5
E. faecalis VR (n = 37) Tedizolid 0.12 to 0.5 0.25 0.5 100.0 0.0 0.0 — — —
Linezolid 0.25 to 2 1 2 100.0 0.0 0.0 100.0 0.0 0.0
Ampicillin 0.5 to N16 1 2 91.9 0.0 8.1 92.3 0.0 7.7
Daptomycin 0.25 to 4 1 2 100.0 0.0 0.0 — — —
Levoﬂoxacin 0.25 to N32 32 N32 10.8 0.0 89.2 10.3 0.0 89.7
Tigecycline ≤0.015 to 0.25 0.06 0.12 100.0 0.0 0.0 100.0 0.0 0.0
Vancomycin N16 to N32 N32 N32 0.0 0.0 100.0 0.0 0.0 100.0
E. faecalis VS (n = 829) Tedizolid ≤0.015 to 1 0.25 0.5 99.39 — — — — —
Linezolid ≤0.25 to 2 1 2 100.0 0.0 0.0 100.0 0.0 0.0
Ampicillin ≤0.12 to N16 1 1 99.6 0.0 0.4 99.5 0.1 0.4
Daptomycin ≤0.06 to 4 1 2 100.0 0.0 0.0 — — —
Levoﬂoxacin ≤0.03 to N32 1 N32 70.2 0.4 29.4 70.6 0.0 29.4
Tigecycline ≤0.008 to 0.25 0.06 0.12 100.0 0.0 0.0 100.0 0.0 0.0
Vancomycin 0.12 to 4 1 2 100.0 0.0 0.0 100.0 0.0 0.0
Enterococcus faecium (n = 372) Tedizolid 0.03 to 4 0.25 0.5 — — — — — —
Linezolid 0.12 to 32 2 2 99.2 0.0 0.8 99.2 0.0 0.8
Ampicillin ≤0.12 to N16 N16 N16 16.7 0.0 83.3 15.4 1.3 83.3
Daptomycin ≤0.06 to N4 2 4 97.0 0.0 3.0 — — —
Levoﬂoxacin 0.25 to N32 N32 N32 14.2 1.9 83.9 16.1 0.0 83.9
Tigecycline ≤0.008 to 1 0.06 0.12 98.1 0.0 1.9 98.1 0.8 1.1
Vancomycin ≤0.25 to N32 N16 N32 45.2 0.5 54.3 45.2 0.0 54.8
E. faecium VR (n = 202) Tedizolid 0.12 to 4 0.25 0.5 — — — — — —
Linezolid 1 to 32 2 2 98.5 0.0 1.5 98.5 0.0 1.5
Ampicillin ≤0.12 to N16 N16 N16 1.0 0.0 99.0 1.0 0.0 99.0
Daptomycin ≤0.5 to N4 2 4 97.5 0.0 2.5 — — —
Levoﬂoxacin 1 to N32 N32 N32 1.0 0.0 99.0 1.0 0.0 99.0
Tigecycline ≤0.015 to 1 0.06 0.12 97.5 0.0 2.5 97.6 0.5 1.9
Vancomycin N16 to N32 N32 N32 0.0 0.0 100.0 0 0 100
E. faecium VS (n = 168) Tedizolid 0.03 to 1 0.25 0.5 — — — — — —
Linezolid 0.12 to 2 2 2 100.0 0.0 0.0 100.0 0.0 0.0
Ampicillin ≤0.12 to N16 N8 N16 35.7 0.0 64.3 32.7 3.0 64.3
Daptomycin ≤0.06 to N4 2 4 96.4 0.0 3.6 — — —
Levoﬂoxacin 0.25 to N32 N4 N32 30.3 4.2 65.5 34.5 0.0 65.5
Tigecycline ≤0.008 to 0.5 0.06 0.12 98.8 0.0 1.2 98.8 1.2 0.0
Vancomycin ≤0.25 to 4 0.5 1 100.0 0.0 0.0 100.0 0.0 0.0
BHS=β-hemolytic streptococci; CoNS=coagulasenegative staphylococci; I= intermediate;MRSA=methicillin-resistant Staphylococcus aureus;MSSA=methicillin-susceptible Staph-
ylococcus aureus; R= resistant; S= susceptible; TMS= trimethoprim/sulfamethoxazole; VGS= viridans group streptococci; VR= vancomycin resistant; VS= vancomycin susceptible;
−- = no breakpoint available.
a Includes S. capitis, S. caprae, S. cohnii, S. epidermidis, S. haemolyticus, S. hominis, S. intermedius, S. pasteuri, S. pettenkoferi, S. saprophyticus, S. schleiferi, S. sciuri, S. simulans, S. warneri, and
S. xylosus.
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These tedizolid-resistant MRSA isolates were obtained in 2011 and
2012 and were previously shown to have a linezolid MIC 16 mg/L
(Sahm et al., 2015).
3.3. Activity of tedizolid against coagulase-negative staphylococci
Tedizolid was highly active against 15 species of coagulase-negative
staphylococci (CoNS), with modal MIC, MIC50, and MIC90 0.12 mg/L,
0.12 mg/L, and 0.25 mg/L, respectively. Linezolid MIC ranged from
≤0.008 to N4 mg/L, and MIC50 and MIC90 were 8-fold higher than for
tedizolid, at 1 and 2 mg/L, respectively, although fewer CoNS isolateswere considered linezolid resistant. Most CoNS isolates (99.0%) were
inhibited by tedizolid at MIC ≤0.5 mg/L; 6 isolates (2 with MIC 1 mg/L
and 4 with MIC 4 mg/L) were considered resistant to tedizolid by
EUCAST criteria (resistant category deﬁned as MIC N0.5 mg/L). Resis-
tance rates among CoNS were high for clindamycin, erythromycin, and
levoﬂoxacin; tedizolid was active against isolates that were resistant
to these agents.
3.4. Activity of tedizolid against streptococci
Tedizolid was highly active against BHS, including S. agalactiae,
S. pyogenes, and streptococci of groups C, F, and G. MIC50/MIC90 for
Table 3
Cumulative inhibition by tedizolid at MIC values by pathogen group in the STAR program, 2009–2013.
Organism group or species (n) Number (cumulative percentage) inhibited by tedizolid MIC (mg/L)
≤0.03 0.06 0.12 0.25 0.5 1 2 4
Staphylococcus aureus (7813) 6 (0.1) 13 (0.2) 606 (8.0) 4665 (67.7) 2504 (99.8) 16 (100) 3 (100) 0
MRSA (3234) 2 (0.1) 8 (0.3) 285 (9.1) 1951 (69.4) 975 (99.6) 10 (99.9) 3 (100) 0
MSSA (4579) 4 (0.1) 5 (0.2 ) 321 (7.2) 2714 (66.5) 1529 (99.9) 6 (100) 0 0
CoNS (623) 4 (0.6) 28 (5.1) 292 (52.0) 245 (91.3) 48 (99.0) 2 (99.4) 0 4 (100)
BHS (70) 2 (2.9) 11 (18.6) 35 (68.6) 22 (100) 0 0 0 0
Streptococcus agalactiae (715) 1 (0.1) 6 (1.0) 279 (40.0) 424 (99.3) 5 (100) 0 0 0
Streptococcus pyogenes (684) 2 (0.3) 21 (3.4) 400 (61.8) 261 (100) 0 0 0 0
VGS (51) 7 (13.7) 13 (39.2) 25 (88.2) 6 (100) 0 0 0 0
All other enterococci (35) 0 0 8 (22.9) 18 (74.3) 9 (100) 0 0 0
All other enterococci VS (27) 0 0 7 (25.9) 11 (66.7) 9 (100) 0 0 0
Enterococcus faecalis (868) 4 (0.5) 3 (0.8) 34 (4.7) 503 (62.7) 319 (99.4) 5 (100) 0 0
E. faecalis VS (829) 4 (0.5) 3 (0.8) 31 (4.6) 484 (63.0) 302 (99.4) 5 (100) 0 0
E. faecalis VR (37) 0 0 3 (8.1) 18 (56.8) 16 (100) 0 0 0
Enterococcus faecium (372) 1 (0.3) 0 29 (8.1) 210 (64.5) 127 (98.7) 3 (99.5) 1 (99.7) 1 (100)
E. faecium VS (168) 1 (0.6) 0 12 (7.7) 95 (64.3) 59 (99.4) 1 (100) 0 0
E. faecium VR (202) 0 0 17 (8.4) 113 (64.4) 68 (98.0) 2 (99.0) 1 (99.5) 1 (100)
BHS= β-hemolytic streptococci; CoNS= coagulase negative staphylococci; MRSA, methicillin-resistant Staphylococcus aureus; MSSA=methicillin-resistant Staphylococcus aureus; VGS
= viridans group streptococci; VR = vancomycin resistant; VS = vancomycin susceptible.
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S. agalactiae, S. pyogenes, and other BHS, respectively. In comparison, al-
though linezolid showed good activity against BHS, with 100% of iso-
lates susceptible to treatment, MIC50 and MIC90 for linezolid were at
least 4-fold higher than tedizolid, at 1mg/L for the various streptococcal
species. All isolates of S. pyogenes and other BHS and 99.3% of
S. agalactiae were inhibited at a tedizolid MIC 0.25 mg/L. Based on
both CLSI-approved and EUCAST criteria, all BHS were susceptible to
tedizolid, with MIC ≤0.25 mg/L. Resistance rates for clindamycin and
erythromycin were higher for S. agalactiae (24.8% and 47.3% of isolates,
respectively) than for S. pyogenes (2.9% and 12.9%, respectively).
The activity of tedizolid against viridans group streptococci (VGS),
which included S. anginosus, S. constellatus, and nonspeciated strepto-
cocci, was similar to that against BHS, with MIC50 and MIC90 0.12 mg/L
and 0.25 mg/L, respectively. All isolates were inhibited at a tedizolid
MIC 0.25 mg/L. MIC50 and MIC90 for linezolid against VGS were 0.5
and 1 mg/L, respectively, with 100% susceptibility rates.
3.5. Activity of tedizolid against enterococci
Tedizolidwas active against enterococci regardless of species or van-
comycin resistance phenotype. MIC of tedizolid against enterococci
ranged from ≤0.015 to 4 mg/L, and MIC50 and MIC90 were 0.25 mg/L
and 0.5 mg/L, respectively. In comparison, values for linezolid wereTable 4
Cumulative inhibition by linezolid at MIC values by pathogen group in the STAR program, 200
Number (cumulative percentage) inhibited by linezo
Organism group or species (n) ≤0.03 0.06 0.12 0.25
Staphylococcus aureus (7813) 0 0 1 (b0.1) 7 (0.1)
MRSA (3234) 0 0 0 3 (0.1)
MSSA (4579) 0 0 1 (b0.1) 4 (0.1)
CoNS (623) 2 (0.3) 0 1 (0.5) 6 (1.4)
BHS (70) 1 (1.4) 0 0 0
Streptococcus agalactiae (715) 0 0 1 (0.1) 5 (0.8)
Streptococcus pyogenes (684) 0 0 2 (0.3) 2 (0.6)
VGS (51) 2 (3.9) 1 (5.9) 2 (9.8) 11 (31.4)
All other enterococci (35) 0 0 0 0
All other enterococci VS (27) 0 0 0 0
Enterococcus faecalis (868) 0 0 2 (0.2) 2 (0.5)
E. faecalis VS (829) 0 0 2 (0.2) 1 (0.4)
E. faecalis VR (37) 0 0 0 1 (2.7)
Enterococcus faecium (372) 0 0 2 (0.5) 0
E. faecium VS (168) 0 0 2 (1.2) 0
E. faecium VR (202) 0 0 0 0
BHS= β-hemolytic streptococci; CoNS= coagulase negative staphylococci; MRSA, methicillin
= viridans group streptococci; VR = vancomycin resistant; VS = vancomycin susceptible.4-fold higher, withMIC50 1 to 2mg/L andMIC90 2mg/L. Vancomycin re-
sistance was present in 4.3%, 54.3%, and 31.4% of E. faecalis, E. faecium
and other enterococci, respectively, by CLSI breakpoints, but it did not
affect the activity of tedizolid or linezolid. MIC50 and MIC90 of tedizolid
were 0.25 and 0.5 mg/L against both vancomycin-resistant and
vancomycin-susceptible enterococcal isolates, respectively, although it
should be noted that there are currently no approved CLSI or EUCAST
breakpoints available. Tedizolid was active against E. faecalis isolates
that were levoﬂoxacin resistant and against E. faecium isolates that
were resistant to multiple tested comparators.
Based on the CLSI-approved susceptibility breakpoint of 0.5 mg/L, 5
isolates of E. faecaliswere nonsusceptible to tedizolid with an MIC of 1
mg/L. These isolates were vancomycin susceptible, and all 5 retained li-
nezolid susceptibility, with MICs of 1 mg/L (3 isolates) or 2 mg/L (2 iso-
lates). Five isolates of E. faecium had MIC values N0.5 mg/L (2
vancomycin-resistant isolates and 1 vancomycin-susceptible isolate
with MIC 1 mg/L, 1 vancomycin-resistant isolate with MIC 2 mg/L, and
1 vancomycin-resistant isolate with MIC 4 mg/L).
4. Discussion
This report provides susceptibility data from the STAR program for
tedizolid against a collection of more than 11,000 Gram-positive clinical
isolates obtained between 2009 and 2013 from the United States and9–2013.
lid MIC (mg/L)
0.5 1 2 4 N4
30 (0.5) 1946 (25.4) 5423 (94.8) 397 (99.9) 9 (100)
13 (0.5) 899 (28.3) 2195 (96.2) 116 (99.8) 8 (100)
17 (0.5) 1047 (23.3) 3228 (93.8) 281 (99.9) 1 (100)
170 (28.7) 378 (89.4) 60 (99.0) 2 (99.4)
6 (10.0) 62 (98.6) 1 (100)
119 (17.5) 587 (99.6) 3 (100)
226 (33.6) 454 (100)
26 (82.4) 9 (100)
2 (5.7) 17 (54.3) 15 (97.1) 1 (100)
1 (3.7) 12 (48.1) 13 (96.3) 1 (100)
36 (4.6) 477 (59.6) 351 (100)
34 (4.5) 448 (58.5) 344 (100)
2 (8.1) 27 (81.1) 7 (100)
2 (1.1) 110 (30.6) 255 (99.2) 0 3 (100)
2 (2.4) 45 (29.2) 119 (100)
0 64 (31.7) 135 (98.5) 3 (100)
-resistant Staphylococcus aureus; MSSA=methicillin-resistant Staphylococcus aureus; VGS
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tivity against key Gram-positive pathogens, including those with resis-
tant phenotypes, during the 5-year period of surveillance. Overall,
99.7% of the tested organisms (11,196 of 11,231) were susceptible to
tedizolid at an MIC 0.5 mg/L or lower.
The MIC90 0.5 mg/L for S. aureus and enterococci and MIC90 0.25
mg/L for CoNS, BHS, and VGS documented in this analysis were consis-
tent with those reported in a previous surveillance report for Gram-
positive isolates collected from the United States and Europe in 2011
and 2012 (Sahm et al., 2015). Also, as shown previously, tedizolidmain-
tained at least 4-fold greater potency than linezolid against all pathogen
groups, although pathogens were susceptible to linezolid by CLSI and
EUCAST criteria.
Resistance to oxazolidinones is conferred mainly by chromosomal
mutations that affect 23S rRNA or ribosomal proteins L3 and L4 and by
the presence of the cfrmethyltransferase gene. Thirty-ﬁve of the isolates
in this report had reduced susceptibility or were resistant to tedizolid,
with MICs that ranged from 1 to 4 mg/L, and 9 of these had a tedizolid
MIC exceeding 1 mg/L. In the 2011–2012 surveillance report, 9 of
10 isolates that had a tedizolid MIC N1 mg/L (3 S. aureus, 5 CoNS, and
1 E. faecium) all had 23s rRNA or ribosomal protein mutations and
had high MIC values for linezolid (Sahm et al., 2015). In that study,
4 linezolid-resistant isolates of S. aureus (MIC 16 mg/L) carried the
cfr gene but were susceptible to tedizolid (MIC 0.5–1 mg/L).
Structure–activity relationship studies have shown that the more com-
pact hydroxymethyl A-ring side chain of tedizolid makes cfr-mediated
methylation of 23s rRNA and its interference with antibiotic binding
more difﬁcult, compared with linezolid and other oxazolidinones
(Kaminska et al., 2010; Locke et al., 2010a; Long et al., 2006; Smith
and Mankin, 2008).
These results from 5 years of the STAR program conﬁrm high
tedizolid susceptibility rates among target pathogens from US and
European centers between 2009 and 2013 and potent antimicrobial ac-
tivity, through the surveillance program. The number of nonsusceptible
isolates of S. aureus, CoNS, and enterococci was limited, and all strepto-
cocci remained highly susceptible to tedizolid. Continued surveillance is
warranted to track the continued potent activity of tedizolid and for
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